The goal of this observational study is to learn about cardiac safety monitoring after thoracic radiotherapy in adults with thoracic tumors.
The main question it aims to answer is:
Dose dynamic monitoring of cardiac biomarkers, electrocardiography, echocardiography, peripheral blood immune cell subsets, cytokines, chemokines, lipid profiles, and lipid metabolism markers help identify early clinical or subclinical cardiac changes after thoracic radiotherapy? Are cardiac substructure radiation dose parameters associated with early cardiac safety outcomes? Participants receiving thoracic radiotherapy as part of their regular medical care will complete cardiac safety assessments at the end of radiotherapy, 1 month after radiotherapy, and 3 months after radiotherapy.
None
None
Patients diagnosed with lung cancer, metastatic lung cancer, esophageal cancer, breast cancer, or thymic tumors who received thoracic radiotherapy.
Cohort
Prospective
Not listed
cardiac safety
Click on the lead sponsor to view all of their trials.
Hebei Medical University Fourth Hospital
Lead sponsor
National Natural Science Foundation of China
Collaborator
